<?xml version="1.0" encoding="UTF-8"?>
<p>The rationale of using immunosuppressants in the management of SARS-CoV-2-associated pneumonia comes from several reports of cases of hyper inflammation and cytokine storms in the lungs of SARS-CoV-2 patients [
 <xref rid="B108" ref-type="bibr">108</xref>]. These agents have been investigated in previous coronavirus outbreaks and are currently being investigated for SARS-CoV-2 with promising preliminary results for some of these agents [
 <xref rid="B109" ref-type="bibr">109</xref>].
</p>
